Moderna's cancer vaccine is 'likely' to get approved. Skeptics question if it will be the best option.
Merck & Co Inc MRK
News
Moderna's cancer vaccine hits its targets, but a data leak rattled investors and the stock tumbled
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Moderna has a plan to revolutionize how certain cancers are treated. We're about to find out its potential in melanoma.
7 healthcare stocks that stand out as investors pay up for the sector
7 healthcare stocks that stand out as -2-
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Big pharma stocks close near all-time highs as tech selloff pushes investors toward safer bets
Formycon Shares Jump After FDA Accepts Application for Keytruda Biosimilar
Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
Halozyme Wins Injunction Against Merck in Keytruda Patent Case — Update
Halozyme Granted Another Injunction Against Merck in Keytruda Patent Case
Tempus Enters Multiyear Collaboration With Moderna, Merck Aimed at Commercializing Cancer Drug
Vaxcyte Reports Bacterial-Infection Vaccine Met Primary Endpoints in Phase 3 Trial
Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
Citi tells investors it's time to sell Moderna after 600%-plus stock gains
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Merck in License Pact Worth Up to $2.13 Billion With SciBrunch Therapeutics — Update
United States